代谢重编程在结直肠癌和药理干预中的作用
Yi Chen1, Jianbing Dong2, Jiameng Miao3
1College of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
International immunopharmacology
|November 20, 2025
概括
针对结直肠癌 (CRC) 的代谢重编程提供了一个有前途的精确治疗方法. 未来的研究应该整合多组学和临床试验,以克服耐药性,并确定组合代谢和免疫疗法的生物标志物.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 瘤发生的起源
背景情况:
- 代谢重编程是癌症的一个关键标志,驱动着结直肠癌 (CRC) 的发展和转移.
- 瘤微环境的改变,包括代谢和免疫因素,促进瘤细胞的增殖和扩散.
研究的目的:
- 审查CRC中的代谢重编程.
- 检查针对代谢重编程的药物干预措施.
- 讨论这些策略的临床应用和挑战.
主要方法:
- 在CRC中对代谢重编程的文献综述.
- 干预策略的分析:微环境修饰,酶抑制,基质剥夺.
- 翻译医学和临床应用的讨论.
主要成果:
- 代谢重编程对于CRC进展至关重要.
- 干预策略显示出潜力,但面临临临床翻译挑战.
- 瘤异质性和耐药性是重要的障碍.
结论:
- 针对代谢重编程是CRC精度治疗的一个有希望的策略.
- 临床转换需要解决瘤异质性和耐药性问题.
- 未来的研究应该结合多组学与临床试验,以发现生物标志物和针对新陈代谢和免疫检查点的组合疗法.
相关概念视频
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K


